版本:
中国

BRIEF-Loxo Oncology announces FDA clearance of investigational new drug application for next-generation trk inhibitor

May 30 Loxo Oncology Inc

* Loxo Oncology announces fda clearance of investigational new drug (ind) application for next-generation trk inhibitor, loxo-195

* Loxo-195 will initially be studied in a multi-center phase 1/2 trial

* Loxo Oncology inc says primary objective of trial is to determine maximum tolerated dose or recommended dose for further study

* Trial will include a dose escalation phase and dose expansion phase

* Loxo Oncology - loxo-195 will be developed as sequential treatment, to follow larotrectinib/another trk inhibitor, to extend time for trk inhibition benefit Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐